Fig 1: Colorectal cancer (CRC) patients have decreased HAPLN1 protein in tumors. (A) Colon tissues were collected from tumors and normal tissue adjacent to the tumor from CRC patients (n = 59). Tissues were sectioned and stained with HAPLN1 antibody by immunohistochemistry (low magnification scale bar = 200 μm; high magnification scale bar = 50 μm). (B) The area of HAPLN1 staining in all stages of CRC patients was normalized to the total area of the colon section. (C) The area of HAPLN1 staining in early (stages I and II, n = 36) and severe stages (stages III and IV, n = 18) of CRC patients was normalized to the total area of the colon section. Results are mean ± SEM. **P < 0.01, ****P < 0.0001 compared with a normal tissue adjacent to the tumors from CPC patients. # P < 0.05 compared with early stage tumour of CPC patients.
Fig 2: Schematic of HAPLN1 regulation of collagen and tumor growth. Decreased HAPLN1 expression leads to increased collagen deposition via pSmad2/3 in the TGF-β signaling pathway, resulting in tumor growth. Restoring HAPLN1 levels can reduce collagen and inhibit tumor growth.
Fig 3: HAPLN1 overexpression increases HAPLN1 but decreases COL1A1 proteins in human colorectal cancer (CRC) epithelial cells. HAPLN1 overexpression plasmids conjugated with GFP were transfected into human CRC epithelial (Caco-2) cells. (A) GFP-positive cells were assessed over a time course of transfection (0, 6, 12, 24, and 48 h) by immunofluorescence (n = 4, scale bar = 100 μm), and (B) GFP-positive cells were normalized to total cells (per view). (C) HAPLN1 and COL1A1 proteins were assessed in cell lysates over a time course of HAPLN1 overexpression plasmid transfection (0, 6, 12, 24, and 48 h) by immunoblot. Fold changes of densitometry of HAPLN1 (D) and COL1A1 (E) were normalized to β-actin. n = 4. Results are mean ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 compared with cells 0 h after HAPLN1 overexpression plasmid transfection. # P < 0.05, #### P < 0.0001 compared with cells 48 h after HAPLN1 overexpression plasmid transfection.
Fig 4: HAPLN1 overexpression reduces tumor cell growth in colorectal cancer (CRC). Human CRC epithelial (Caco-2) cells were transfected with HAPLN1 overexpression or negative control plasmid, and vehicle controls received media. Cells were then challenged with human recombinant TGF-β protein. (A) Live cells were enumerated during the time course of TGF-β challenge (0, 6, 12, and 24 h) using a cell viability assay. (B) Cells were stained with crystal violet after 24 h of TGF-β challenge and (C) visualized using light microscopy (scale bar = 100 um). (D) Cell migration was assessed by boyden’s chamber assay after 24 hours TGF-β challenge that Caco-2 cells were stained with crystal violet (scale bar = 100 um) and (E) migrated were counted in at least 5 random fields per well under 20x magnification lens by an inverted microscope. (F) Cell Scratch assays were performed in wells cultured with Caco-2 cells, and cancer cell invasion and migration were assessed by wound healing (scale bar = 200 um). (G) Wound area was assessed by measuring wound closure size after 0, 6, 12, and 24 h post-scratch. n = 4. Results are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with control cells. # P < 0.05, #### P < 0.0001 compared with cells transfected with negative control plasmid.
Fig 5: HAPLN1 regulates collagen via the TGF-β signaling pathway and E-cadherin to control tumor growth in colorectal cancer (CRC). Human CRC epithelial (Caco-2) cells were transfected with HAPLN1 overexpression or negative control plasmid, and vehicle controls received media. Cells were then challenged with human recombinant TGF-β protein. (A) Cells were stained with HAPLN1 and COL1A1 fluorescent antibody after 24 h of TGF-β and assessed by immunofluorescence (scale bar = 100 μm). (B) HAPLN1 and COL1A1 proteins were assessed in cell lysates by immunoblot. Fold change of densitometry of HAPLN1 (C) and COL1A1 (D) was normalized to β-actin. (E) Smad2, Smad3, Smad4, and COL1A1 proteins in human colon healthy controls and tumors from CRC patients by immunohistochemistry in the Pathology Atlas database (scale bar = 200 μm). (F) Smad2/3, Smad4, p-Smad2/3, and E-cadherin proteins were assessed in cell lysates by immunoblot. Fold change of densitometry of Smad2/3 (G), Smad4 (H), p-Smad2/3 (I), and E-cadherin (J) was normalized to β-actin. n = 4. Results are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with control cells receiving media. # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001 compared with cells transfected with negative control plasmid.
Supplier Page from Sino Biological, Inc. for Human HAPLN1 Gene ORF cDNA clone expression plasmid, C-GFPSpark tag